Ad is loading...
DCXIX
Price
$9.43
Change
+$0.01 (+0.11%)
Updated
Nov 15 closing price
PCRCX
Price
$10.56
Change
+$0.01 (+0.09%)
Updated
Nov 15 closing price
Ad is loading...

DCXIX vs PCRCX

Header iconDCXIX vs PCRCX Comparison
Open Charts DCXIX vs PCRCXBanner chart's image
Catalyst/Millburn Dynamic Cmdty Stgy I
Price$9.43
Change+$0.01 (+0.11%)
VolumeN/A
CapitalizationN/A
PIMCO Commodity Real Ret Strat C
Price$10.56
Change+$0.01 (+0.09%)
VolumeN/A
CapitalizationN/A
DCXIX vs PCRCX Comparison Chart
Loading...
View a ticker or compare two or three
VS
DCXIX vs. PCRCX commentary
Nov 18, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is DCXIX is a Buy and PCRCX is a Hold.

FUNDAMENTALS
Fundamentals
PCRCX has more cash in the bank: 3.56B vs. DCXIX (8.95M). PCRCX pays higher dividends than DCXIX: PCRCX (0.59) vs DCXIX (0.00). DCXIX was incepted earlier than PCRCX: DCXIX (9 years) vs PCRCX (22 years). PCRCX is a more actively managed with annual turnover of: 77.00 vs. DCXIX (58.00). PCRCX has a lower initial minimum investment than DCXIX: PCRCX (1000) vs DCXIX (2500). DCXIX annual gain was more profitable for investors over the last year : 3.74 vs. PCRCX (-1.17). PCRCX return over 5 years is better than : 34.03 vs. DCXIX (1.14).
DCXIXPCRCXDCXIX / PCRCX
Total Expense RatioN/AN/A-
Annual Report Gross Expense RatioN/AN/A-
Fund Existence9 years22 years-
Gain YTD1.8360.294625%
Front LoadN/AN/A-
Min. Initial Investment25001000250%
Min. Initial Investment IRAN/A1000-
Net Assets8.95M3.56B0%
Annual Yield % from dividends0.000.59-
Returns for 1 year3.74-1.17-318%
Returns for 3 years7.70-5.40-143%
Returns for 5 years1.1434.033%
Returns for 10 yearsN/A-9.74-
View a ticker or compare two or three
Ad is loading...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
SOUHY11.480.18
+1.59%
South32 Ltd.
CURLF2.220.02
+0.91%
Curaleaf Hldgs Inc.
KYCCF417.252.25
+0.54%
Keyence Corp.
PVCT0.11N/A
-0.81%
Provectus Biopharmaceuticals, Inc.
CGEMY32.38-1.40
-4.14%
Capgemini SE